Skip to Content

Stem Cells Spin SA SCS

Morningstar Rating
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

SCS is trading at a 49% discount.
Price
PLN 0.56
Fair Value
PLN 1.34
Uncertainty
Extreme
1-Star Price
PLN 8.81
5-Star Price
PLN 6.54
Economic Moat
Ndhc
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SCS is a good fit for your portfolio.

Trading Information

Previous Close Price
Day Range
52-Week Range
Bid/Ask
/
Market Cap
Volume/Avg
/

Key Statistics

Price/Earnings (Normalized)
Price/Sales
46.99
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Stem Cells Spin SA is a biotechnology company. The company is engaged in the development, production, marketing and sale of natural regenerative products for the dermocosmetic and veterinary care markets, as well as applications for the human and veterinary medical industry. Its products include NHAC Biocervin MIC-1, Revitacell, PRS MIC-1 and Velvetyna.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Growth
Total Number of Employees
1

Valuation

Metric
SCS
Price/Earnings (Normalized)
Price/Book Value
2.62
Price/Sales
46.99
Price/Cash Flow
15.75
Price/Earnings
No chart available

Financial Strength

Metric
SCS
Quick Ratio
0.44
Current Ratio
4.61
Interest Coverage
−105.28
Quick Ratio
SCS

Profitability

Metric
SCS
Return on Assets (Normalized)
1.04%
Return on Equity (Normalized)
2.02%
Return on Invested Capital (Normalized)
1.98%
Return on Assets
SCS
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRFfmwfhwbQpq$570.1 Bil
VRTX
Vertex Pharmaceuticals IncYvhpwmjlQndfvmn$108.0 Bil
REGN
Regeneron Pharmaceuticals IncYmzrhdghkSzgzr$105.6 Bil
MRNA
Moderna IncPfykwshjJsrk$40.8 Bil
ARGX
argenx SE ADRDvgpmcczHzd$23.5 Bil
BNTX
BioNTech SE ADRHwglpxnYgbs$21.9 Bil
ALNY
Alnylam Pharmaceuticals IncFmxhdxxhxJztzwyt$18.8 Bil
BMRN
Biomarin Pharmaceutical IncZpqxcfwqYprfgfg$16.5 Bil
RPRX
Royalty Pharma PLC Class ALvmfyvwnbRvrlzjr$13.6 Bil
INCY
Incyte CorpZxdjgchjLxbghq$12.8 Bil

Sponsor Center